Mahathir Bayena

Ensysce Biosciences (NASDAQ:ENSC) announced completion of enrollment in Part 3 of the PF614-MPAR-102 clinical study, evaluating its MPAR overdose-protection technology for opioid medicines.

Axsome Therapeutics (NASDAQ:AXSM) announced that the first patient has been dosed in SUMMIT, a Phase 3 trial evaluating AXS-05 for smoking cessation in adult smokers.

Karyopharm Therapeutics (NASDAQ:KPTI) submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval for XPOVIO (selinexor) combined with ruxolitinib to treat patients with myelofibrosis.

Aon (NYSE:AON) signed a definitive agreement to acquire USI from KKR and other shareholders for $17 billion, expanding its U.S. insurance brokerage operations.

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second interim overall survival results from the Phase 3 HERIZON-GEA-01 trial showing Ziihera (zanidatamab-hrii) plus chemotherapy improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma.

Alvotech (NASDAQ:ALVO) announced that the U.S. Food and Drug Administration accepted its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) in prefilled syringe and autoinjector formats.

Belgian authorities are seeking crypto wallet data from EU domain registrars as part of a piracy investigation.

Vietnam has not issued its first crypto exchange licence, but five firms passed an initial review.

Cobre (ASX:CBE) increased its holding to a controlling majority in the Sierra Atacama Copper Project.

Way2VAT (ASX:W2V) reported $4 million in first-half revenue, marking a 61% increase compared to the prior corresponding period.